博瑞医药(688166.SH)：待完成国内III期临床研究，并经国家药监局审评、审批通过后方可在国内生产上市

Core Viewpoint - The company BoRui Pharmaceutical (688166.SH) has successfully completed the enrollment phase of its Phase III clinical trials for the BGM0504 injection, targeting type 2 diabetes and weight loss indications, and is currently in the administration and follow-up stages [1] Group 1 - The Phase III clinical trials for BGM0504 have completed all patient enrollments and are progressing as planned [1] - The trials are focused on two indications: type 2 diabetes and weight loss [1] - The company anticipates that the drug will be available for production and market launch in China following the completion of the clinical research and approval from the National Medical Products Administration [1]